Eli Lil­ly plots NDA as sec­ond JAK study backs baric­i­tinib for alope­cia area­ta; Al­ny­lam heads to FDA af­ter full vutrisir­an da­ta pan out

Eli Lil­ly has post­ed pos­i­tive da­ta from its sec­ond Phase III study test­ing its JAK in­hibitor baric­i­tinib in spurring hair re­growth among pa­tients suf­fer­ing from se­vere alope­cia area­ta.

In­ves­ti­ga­tors re­port­ed a dose-de­pen­dent re­sponse to the drug, with 35% of the sub­jects in the 4 mg arm achiev­ing 80% or more scalp hair cov­er­age against 22% in the 2 mg arm. That’s in line with the first Phase III read­out.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.